Hospital-Acquired Lung infection Treatment with novel inhaled Anti-Microbial Resistance Beta-lactamase inhibitors (HALT-AMR)

Purpose and goal

Antimicrobial resistance is a growing global crisis that threatens our ability to treat life-threatening infections. The HALT-AMR project aims to develop an inhalation therapy that protects antibiotics against resistant bacteria by delivering the drug directly to the infection in the lungs via a dry powder inhaler. This allows for high local concentration and efficient uptake in the lungs, which increases the drug´s efficacy and reduces the risk of resistance and systemic side effects.

Expected effects and result

We will demonstrate the preclinical safety, pharmacokinetics and efficacy of APC14. In summary, the project aims to develop and clinically test an innovative inhalation therapy that can reverse the development of antibiotic resistance in lung infections by protecting the antibiotic and delivering it effectively to the site of infection in the lungs.

Planned approach and implementation

The project starts with preclinical studies of efficacy and toxicology (WP1-2) and development of dry powder formulation (WP3). När GMP-material is ready to conduct the first clinical study in humans, a so-called First-in-Human Single Ascending Dose study (WP4) to evaluate safety, tolerance and pharmacokinetics. Project management (WP5) and protection of intellectual property rights (WP6) are ongoing throughout the project. The study (WP4) takes place at CTC in Uppsala.